Member Login Area
Member Icon Login
Member Login
Member Icon Close

Brochure / Flyer

Brochure
Flyer
Veeda Brochure
02. Large Molecule Capabilities & Experience
03. Veeda Patient Based Clinical Trials Experience
04. Psychiatry Trials Capabilities of Veeda
05. Glucose Clamp Study Capabilities of Veeda
06. Veeda Biosimilar Capabilities
07. Veeda's expertise in handling Inhalation studies
08. Pharmacovigilance Services
09. Oncology Trials Capabilities of Veeda
10. Veeda Clinical Research Experience & Capabilites
Veeda Flyer
01. Veeda Completes 20th Patient Based Pharmacokinetic Study Sucessully
02. VEEDA CRO deliberated a talk on Study Design Considerations of Bioequivalence Studies

in the workshop organized by CDSCO – New Delhi
03. ASSOCHAM Pharma Excellence Awards 2018 privileged Veeda Clinical Research with

"BEST CLINICAL RESEARCH 2018 "award
04. Renal Cell Carcinoma PK studies
File Size : 302 KB
Last Update : 28 Nov 2014
File Information : Patient based PK studies in Renal Cell Carcinoma.
05. Ophthalmology Pharmacokinetic studies
File Size : 316 KB
Last Update : 28 Nov 2014
File Information : Pharmacokinetic studies for ophthalmic products in aqueous humor of eye.
06. Topical Products Clinical Endpoint studies
File Size : 163 KB
Last Update : 28 Nov 2014
File Information : BE studies with clinical end-points for topical products in different patient population.
07. Long Acting Anti-Psychotic Injections
File Size : 336 KB
Last Update : 28 Nov 2014
File Information : Long acting antipsychotic injection in psychiatric population.
08. Liposomal Doxorubicin PK studies
File Size : 339 KB
Last Update : 28 Nov 2014
File Information : Liposomal Doxorubicin Injection PK studies for bioequivalence
12. Outlook-towards-Indian-CROs
13. NCE Bio analysis Capabilities
16. Simplifying the patient-based clinical trials processes for improved outcome
19. Long acting injectable Anti-psychotics
20. USFDA-Data Integrity Inspection
22. Protein bound nano particles
24. Training of Drug inspectors by CDSCO
25. USFDA - BioResearch Monitoring Program
26. Special Studies Capabilities like patch studies
27. Bioanalytical methods for Challenging molecules

Our exemplary regulatory track record

USFDA
33 times
Brazil ANVISA
7 times
WHO
5 times
UK MHRA
3 times
EU - AGES
1 times
South Africa - MCC
1 times
NPRA - Malaysia
4 times
DCGI
13 times